US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco S&P SmallCap Health Care ETF

51.63

+0.35410.69%

Post-market: 51.640.0069+0.01%19:30 EDT

Volume:8K

Turnover:410.51K

Market Cap:175.04M

PE:- -

High:51.99

Open:51.57

Low:51.54

Close:51.28

52wk High:56.45

52wk Low:39.08

Shares:3.39M

Float Shares:3.39M

Volume Ratio:0.38

T/O Rate:0.23%

Dividend:0.00

Dividend Rate:0.01%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study

The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1

THOMSON REUTERS

Krystal Biotech (KRYS) Rallies On Pipeline Hopes But Is The Valuation Already Priced In

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT)

Corcept Therapeutics Director David L. Mahoney Sells 103,606 Shares Worth $12.26 Million

Regeneron’s Pasatru granted FDA approval for FOP

Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray

Femasys announces FDA approval of FemBloc modular premarket approval application

Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million

Amylyx Phase 3 data support FDA approval, says Citi

Corcept Therapeutics Incorporated : Truist Securities Assumes Coverage with Buy Rating; Target Price $164 vs $50

THOMSON REUTERS

Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99

Health Insurers are Dumping Medicare Advantage Plans. Here's How Many Seniors Could be Affected.

Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares

Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says

MT Newswires Live

Krystal Biotech, Inc. : RBC Initiates Coverage with Outperform Rating; Target Price $400

THOMSON REUTERS

BrightSpring Health Svcs Price Target Maintained with a $90.00/Share by BTIG

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/PSCH/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSCH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSCH\",,,,,undefined,":{"symbol":"PSCH","market":"US","secType":"STK","nameCN":"Invesco S&P SmallCap Health Care ETF","latestPrice":51.6331,"timestamp":1790971200000,"preClose":51.279,"halted":0,"volume":7949,"hourTrading":{"tag":"盘后","latestPrice":51.64,"preClose":51.6331,"latestTime":"19:30 EDT","volume":9,"amount":464.6324,"timestamp":1790983802989,"change":0.0069,"changeRate":0.000134,"amplitude":0},"delay":0,"changeRate":0.006905360868971614,"floatShares":3390000,"shares":3390000,"eps":0,"marketStatus":"Market Closed","change":0.3541,"latestTime":"10-02 16:00:00 EDT","open":51.57,"high":51.99,"low":51.54,"amount":410508.641047,"amplitude":0.008776,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":51.279,"sharesOutstanding":3220000,"nav":51.29067,"aum":175109072.55,"dividendRate":0.000058,"bidAskSpread":0.001911,"postHourTrading":{"tag":"盘后","latestPrice":51.64,"preClose":51.6331,"latestTime":"19:30 EDT","volume":9,"amount":464.6324,"timestamp":1790983802989,"change":0.0069,"changeRate":0.000134,"amplitude":0},"volumeRatio":0.3820202063487071,"impliedVol":0.1092,"impliedVolPercentile":0.7371},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSCH\",,,,,undefined,":{"symbol":"PSCH","floatShares":3390000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3820202063487071,"shares":3390000,"dividePrice":0.003,"high":51.99,"amplitude":0.008776,"preClose":51.279,"low":51.54,"week52Low":39.08,"pbRate":"--","week52High":56.454,"institutionHeld":0,"latestPrice":51.6331,"eps":0,"divideRate":0.000058,"volume":7949,"delay":0,"ttmEps":0,"open":51.57,"prevYearClose":44.0553,"prevWeekClose":52.7945,"prevMonthClose":52.07,"prevQuarterClose":52.07,"fiveDayClose":52.7945,"twentyDayClose":54.7539,"sixtyDayClose":54.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSCH\",params:#limit:5,,,undefined,":[{"date":"2026-03-23","symbol":"PSCH","amount":0.00033,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-09-22","symbol":"PSCH","amount":0.00259,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"PSCH","amount":0.00199,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-24","symbol":"PSCH","amount":0.01419,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSCH","amount":0.01801,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"Invesco S&P SmallCap Health Care ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSCH\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.01949,"currency":"USD"},{"executeDate":"2018-09-24","recordDate":"2018-09-25","paymentDate":"2018-09-28","value":0.00522,"currency":"USD"},{"executeDate":"2022-03-31","recordDate":null,"paymentDate":"2022-03-31","value":3,"currency":"USD"},{"executeDate":"2023-12-18","recordDate":"2023-12-19","paymentDate":"2023-12-22","value":0.00448,"currency":"USD"},{"executeDate":"2024-03-18","recordDate":"2024-03-19","paymentDate":"2024-03-22","value":0.03613,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSCH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSCH\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662620199","title":"Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2662620199","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662620199?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610625,"startTime":"0","endTime":"0","summary":"Alkermes’ alixorexton posts positive Phase 2 Vibrance-1 results in narcolepsy type 1 studyAlkermes reported publication of positive Phase 2 Vibrance-1 results for alixorexton in adults with narcolepsy type 1 in The Lancet Neurology.Results were previously announced, not newly presented, showing improved daytime wakefulness and sleepiness measures versus placebo.Study also indicated reduced cataplexy at one dose, with broader patient-reported benefits in daily functioning.Safety profile appeared generally well tolerated, with mostly mild-to-moderate adverse events and no serious treatment-emergent events reported.Positive Phase 2 readouts supported the launch of the global Phase 3 Brilliance program testing once-daily and split-dose regimens in narcolepsy types 1 and 2.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL56tjq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","PSCH","MEDX","BK4139","IBRN","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201993","title":"The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201993?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA7VQ936:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","BK4139","MEDX","IBRN","PSCH","FBT","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661652248","title":"Krystal Biotech (KRYS) Rallies On Pipeline Hopes But Is The Valuation Already Priced In","url":"https://stock-news.laohu8.com/highlight/detail?id=2661652248","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661652248?lang=en_us&edition=fundamental","pubTime":"2026-08-23 17:16","pubTimestamp":1787476617,"startTime":"0","endTime":"0","summary":"Krystal Biotech stock performance snapshot\nKrystal Biotech (KRYS) has attracted fresh attention after recent share price gains, with the stock closing at $346.58 on 19 August 2026. Investors are weighing these moves against its recent return profile and fundamentals.\nOver the past month the stock shows a 3.4% return, with about 15.7% in the past 3 months and 40.4% year to date. Its 1 year total return is 130.3%, while the 3 year figure is approximately 1.7 times and the 5 year total return is...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-rallies-on-pipeline-hopes-but-is-the-va","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-rallies-on-pipeline-hopes-but-is-the-va","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KRYS","BK4581","BK4588","HELX","PSCH","BK4585","XBI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661262741","title":"Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Alvotech (ALVO) and Abbott Laboratories (ABT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2661262741","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661262741?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:00","pubTimestamp":1787310037,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Corcept Therapeutics (CORT), Alvotech (ALVO) and Abb...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-corcept-therapeutics-cort-alvotech-alvo-and-abbott-laboratories-abt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-corcept-therapeutics-cort-alvotech-alvo-and-abbott-laboratories-abt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2324357040.USD","BK4082","LU0566484027.USD","LU0868494617.USD","LU0058720904.USD","BK4139","IE00B2B36J28.USD","LU2237957902.USD","LU2211815571.USD","IE00B4R5TH58.HKD","CORT","BK4581","BK4568","SG9999002224.SGD","FBT","LU0432979614.USD","LU1721429402.USD","LU0208291251.USD","LU0029874061.USD","HCSG","LU1023059063.AUD","LU1721429741.USD","LU1559883803.SGD","LABU","ALVO","LU0266013472.USD","LU2112291526.USD","PJP","LU1914381329.SGD","LU2133065610.SGD","IHI","LU0070302665.USD","PSCH","ABT","IE00BFTCPJ56.SGD","LU2237957811.SGD","LU0122379950.USD","BK4137","LU0320765489.SGD","LU0211331839.USD","TMED","IE0009355771.USD","BK4007","SGXZ41872573.SGD","LU0882574055.USD","XLV","XBI","LU0234572021.USD","SG9999002232.USD","BK4592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661129232","title":"Corcept Therapeutics Director David L. Mahoney Sells 103,606 Shares Worth $12.26 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661129232","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661129232?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:30","pubTimestamp":1787257853,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics director David L. Mahoney sells 103,606 shares worth $12.26 millionCorcept director David L. Mahoney sold 103,606 shares on Aug. 18.Sales priced at $117.47 to $119.64, weighted-av","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL759h51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Therapeutics Director David L. Mahoney Sells 103,606 Shares Worth $12.26 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4532","CORT","PSCH","LU0566484027.USD","BK4007","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660287604","title":"Regeneron’s Pasatru granted FDA approval for FOP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287604","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660287604?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:20","pubTimestamp":1787232025,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has approved Pasatru to reduce new heterotopic ossification and reduce clinician-assessed disease flare-ups i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","MRNY","GDOC","IDNA","MEDI","PSCH","IEIH","LABU","XLVX","BK4585","LFSC","SYNB","GNMX","TECB","PINK","TBXU","IBB","IYH","BBP","BK4588","BMED","RSPH","NVIB","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660028408","title":"Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2660028408","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660028408?lang=en_us&edition=fundamental","pubTime":"2026-08-20 12:43","pubTimestamp":1787200984,"startTime":"0","endTime":"0","summary":"Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) just unveiled an announcement. Glenmark Pharmaceuticals has secured U.S. FDA approval for its F...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","SYNB","IEIH","FRTY","LABU","TBXU","BBP","BMED","NVIB","MEDI","PSCH","GDOC","IYH","GNMX","IBB","PINK","XLVX","TECB","MRNY","LFSC","IDNA","MRNX","BK4588","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660252964","title":"Femasys announces FDA approval of FemBloc modular premarket approval application","url":"https://stock-news.laohu8.com/highlight/detail?id=2660252964","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660252964?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:16","pubTimestamp":1787145413,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced that the FDA has approved the company’s modular premarket approval application pathway for FemBloc, its investigational no...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","RSPH","MEDI","BBP","SYNB","TBXU","FEMY","IYH","BMED","BK4584","BK4539","IDNA","GNMX","GDOC","FRTY","MRNY","PSCH","LABU","TECB","XLVX","BK4585","NVIB","MRNX","IBB","LFSC","BK4588","PINK","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660371492","title":"Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660371492","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660371492?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:31","pubTimestamp":1787085063,"startTime":"0","endTime":"0","summary":"Corcept Chief Business Officer Gary Charles Robb sells 10,000 shares for $1.16 millionCorcept Therapeutics Chief Business Officer Gary Charles Robb sold 10,000 common shares on Aug. 17.Sale priced at ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLc47Ccv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","BK4532","LU1559883803.SGD","PSCH","LU0566484027.USD","CORT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660595493","title":"Amylyx Phase 3 data support FDA approval, says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2660595493","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660595493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:05","pubTimestamp":1787061936,"startTime":"0","endTime":"0","summary":"Citi says Amylyx’s (AMLX) avexitide showed a “highly differentiated” profile in the Phase 3 LUCIDITY study, a 78 participant, placebo-controlled tr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","NVIB","GNMX","MRNX","MEDI","IDNA","PINK","BK4588","SYNB","GDOC","BBP","LABU","PSCH","BMED","FRTY","TBXU","TECB","AMLX","MRNY","IYH","XLVX","LFSC","IEIH","IBB","RSPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660619704","title":"Corcept Therapeutics Incorporated : Truist Securities Assumes Coverage with Buy Rating; Target Price $164 vs $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2660619704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660619704?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:04","pubTimestamp":1787051049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F0P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","BK4532","BK4007","PSCH","FBT","LU1559883803.SGD","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660430568","title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2660430568","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660430568?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:54","pubTimestamp":1787007262,"startTime":"0","endTime":"0","summary":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sells 7,576 shares for $374,301.99Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sold 7,576 ordinary shares on Aug. 17, 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLbv4Lk0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","PSIL","ALKS","BK4139","FBT","IBRN","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659173096","title":"Health Insurers are Dumping Medicare Advantage Plans. Here's How Many Seniors Could be Affected.","url":"https://stock-news.laohu8.com/highlight/detail?id=2659173096","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659173096?lang=en_us&edition=fundamental","pubTime":"2026-08-16 00:16","pubTimestamp":1786810560,"startTime":"0","endTime":"0","summary":"Coverage changes could leave rural markets with fewer choicesAbout 10% of the Medicare Advantage market was forced to find new plans in 2026. Coverage plans for 2027 will be finalized by Oct. 1.Older ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","LU1093756325.SGD","LNGR","BK4566","LU0208291251.USD","LU0348723411.USD","IEHS","LU0256863811.USD","LU0170899867.USD","LU0320765489.SGD","XLVX","LU0070302665.USD","LU1983260115.SGD","LU0417517546.SGD","IYH","BK4585","LU0266013472.USD","SG9999014021.USD","BK4532","PSCH","SG9999014013.SGD","FXH","LU0211331839.USD","LU0390134368.USD","XHS","LU0238689110.USD","LU1093756168.USD","BK4588","SG9999014005.SGD","SG9999014039.USD","BK4154","UNHU","HUM","IHF","MOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659124086","title":"Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659124086","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659124086?lang=en_us&edition=fundamental","pubTime":"2026-08-15 06:23","pubTimestamp":1786746202,"startTime":"0","endTime":"0","summary":"Krystal Biotech Director Dino A. Rossi disposes of USD 8.17 million in common sharesDirector Dino A. Rossi cut his Krystal Biotech stake to 50,000 shares on Aug. 14, 2026.Disposed of 25,000 common sha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL6DCXXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","KRYS","BK4139","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659140246","title":"Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659140246","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659140246?lang=en_us&edition=fundamental","pubTime":"2026-08-14 23:11","pubTimestamp":1786720282,"startTime":"0","endTime":"0","summary":"Krystal Biotech  has further room for gains driven by Vyjuvek, its treatment for the rare blistering condition dystrophic epidermolysis bullosa, alongside international launches and growth across its gene therapy pipeline, RBC Capital said Friday in a report.Krystal's neurotrophic keratitis program could be its next major catalyst, with pivotal data expected in early 2027, RBC said. Shares may rise 30% if results match the current standard of care, while a weak outcome might prompt a 15% decline, the report said.RBC forecasts peak NK sales of $2.1 billion in 2030, citing the established market and potential for the therapy to become a best-in-class treatment, though the outlook remains \"cautiously optimistic\" given limited clinical data.Vyjuvek holds more than 60% of the US market, while international launches are expected to drive the next phase of growth, the report said. RBC projects Vyjuvek peak sales of $1 billion by 2033 and pointed to H2 readouts in ocular DEB, cystic fibrosis a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","KRYS","BK4581","HELX","XBI","PSCH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659428117","title":"Krystal Biotech, Inc. : RBC Initiates Coverage with Outperform Rating; Target Price $400","url":"https://stock-news.laohu8.com/highlight/detail?id=2659428117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659428117?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:39","pubTimestamp":1786700394,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nFWN44B0NL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRYS","PSCH","BK4139","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156635","title":"BrightSpring Health Svcs Price Target Maintained with a $90.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156635?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:03","pubTimestamp":1786618980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BTSG/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4196","LU2089984988.USD","LU2468319806.SGD","BTSG","PSCH","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2495084118.USD","IE00BPRC5H50.USD","LU1979443071.USD","LU0348766576.USD","BMED","LU2242644610.SGD","603259","LU1997244956.HKD","BK1141","LU1719994722.HKD","LU1251922891.USD","MEDI","IBRN","LU2125910500.SGD","SMCO","LU1969619763.USD","LU1997245177.USD","LU2328871848.SGD","BBC","APXH","IE00B5MMRT66.SGD","LFSC","02359","BK1576","FHLC","LU1808992512.USD","IE00B543WZ88.USD","LU0456842615.SGD","LU1934453819.USD","LU0708995583.HKD","XBIX","LU2488822045.USD","PSIL","LU0700851271.USD","IDNA","161027","CXO","LU1303224171.USD","LU0611395673.USD","LU2045819591.USD","PSCH","LU1997245094.SGD","LU0052750758.USD","BK1583","LU0320764599.SGD","BK0216","WX","LU1770034418.SGD","LU1046422090.SGD","LU0348767384.USD","SURI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","LU2242644610.SGD","603259","LU1997244956.HKD","LU1880383366.USD","LU1242518931.SGD","LU0128526141.USD","LU2328871848.SGD","IE00B5MMRT66.SGD","BK1576","LU0819121731.USD","IDNA","CXO","BK1521","LU0051755006.USD","WX","LU0516423174.USD","SG9999002562.SGD","LU0348767384.USD","LU0039217434.USD","IE00BPRC5H50.USD","LU1242518857.USD","BK1141","LU3063872942.SGD","LU0516423091.SGD","KURE","LU0307460666.USD","FHLC","LU0456846285.SGD","LU0348735423.USD","IE00B543WZ88.USD","LU1934453819.USD","LU0516422952.EUR","LU0708995583.HKD","XBIX","PSIL","LU0611395673.USD","LU2045819591.USD","03759","LU0417516902.SGD","LU0456827905.SGD","PSCH","LU1997245094.SGD","LU0052750758.USD","LU1770034418.SGD","LU0979878070.USD","LU0572944931.SGD","SURI","LU2495084118.USD","LU1979443071.USD","BMED","LU1719994722.HKD","MEDI","IBRN","LU2125910500.SGD","SMCO","LU1969619763.USD","LU1997245177.USD","LU0823426308.USD","BBC","LFSC","02359","BK1610","IE00B0JY6N72.USD","LU0359201612.USD","LU1808992512.USD","LU0140636845.USD","LU0326950275.SGD","SG9999002463.SGD","LU2488822045.USD","LU0181495838.USD","161027","LU1303224171.USD","LU0320764599.SGD","BK1583","BK0216","LU1046422090.SGD","LU0043850808.USD","LU1720050803.USD","LU1794554557.SGD","BK1589","LU0417516738.SGD","LU1251922891.USD","LU0348825331.USD","02269","LU0327786744.USD","APXH","LU0588546209.SGD","LU0456842615.SGD","LU0516422366.SGD","LU0856984785.SGD","LU0516422440.USD","LU2039709279.SGD","LU0700851271.USD","LU0823426480.USD","LU0359202008.SGD","LU0029874061.USD","LU1688375341.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659926188","title":"Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2659926188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659926188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:37","pubTimestamp":1786567029,"startTime":"0","endTime":"0","summary":"The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 2026, Outlook Therapeutics announced U.S. FDA approval of LYTENAVA (bev...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","IDNA","BK4539","NVIB","SYNB","XLVX","BBP","BK4007","PSCH","RSPH","GDOC","PINK","FRTY","GNMX","LENZ","BK4588","MRNY","IEIH","TECB","BMED","BK4139","IYH","LABU","MEDI","IBB","BK4585","MRNX","LFSC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}